What's Happening?
Tango Therapeutics, in collaboration with Revolution Medicines, has reported a significant breakthrough in the treatment of pancreatic cancer. Their experimental combination of a PRMT5 inhibitor and a RAS inhibitor has achieved a 92% response rate in patients
with advanced MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC). This response rate surpasses previous results seen with monotherapies or chemotherapy combinations. The data, derived from an ongoing Phase 1/2 study, also showed a 100% disease control rate and a 90% six-month progression-free survival rate among the 12 PDAC patients evaluated. The combination therapy was well-tolerated, with no new safety concerns reported. Tango Therapeutics is now planning to advance to Phase 3 trials, aiming to establish this combination as a first-line treatment for pancreatic cancer.
Why It's Important?
This development is significant as pancreatic cancer is notoriously difficult to treat, with a five-year survival rate of only 13%. The high response rate achieved by Tango and Revolution Medicines' combination therapy offers new hope for patients with limited treatment options. The success of this trial could lead to a new standard of care for pancreatic cancer, potentially improving survival rates and quality of life for patients. The promising results also highlight the potential of targeted combination therapies in oncology, which could pave the way for similar approaches in other hard-to-treat cancers.
What's Next?
Tango Therapeutics plans to expedite the progression to Phase 3 trials for their combination therapy in first-line treatment settings. They are also considering advancing the therapy for second-line treatment, pending regulatory feedback. The company anticipates that the FDA will support their request to move forward, given the unprecedented activity observed in the trial. The outcome of these trials could significantly impact the treatment landscape for pancreatic cancer, offering a new therapeutic option for patients.
